Payment overview · 2025
General Payments
$104,676.79
358 reported records · 32 companies
Healthcare provider profile · identity verified
Hisham A Alrefai, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · LOUISVILLE, KY · NPI 1811962350
Verified facts
What the public records show
CMS Open Payments records show Hisham A Alrefai, MD received $104,676.79 in general payments during 2025 across 358 reported records.
Novo Nordisk Inc accounted for 37.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia, Nexletol, Ozempic, Rybelsus, Synthroid, Unithroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 626 claims for Synthroid by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UNITHROID as an associated drug or biological on 7282 records involving 3230 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Unithroid by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Jardiance by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Nexletol by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Nexlizet by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 818 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Wegovy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $39,648.71 | 37.9% | 52 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $30,102.23 | 28.8% | 47 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $29,510.40 | 28.2% | 54 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $1,651.30 | 1.6% | 3 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $519.20 | 0.5% | 22 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $413.14 | 0.4% | 28 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $344.07 | 0.3% | 4 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$310.22 | 0.3% | 12 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $246.14 | 0.2% | 17 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $239.58 | 0.2% | 15 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $223.71 | 0.2% | 14 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $211.88 | 0.2% | 12 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $168.73 | 0.2% | 12 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $167.51 | 0.2% | 11 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $144.06 | 0.1% | 10 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $116.09 | 0.1% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $90.39 | 0.1% | 5 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $87.57 | 0.1% | 4 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $76.53 | 0.1% | 6 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $64.93 | 0.1% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $60.74 | 0.1% | 3 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $49.64 | 0.1% | 3 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $44.28 | 0.0% | 3 | 2025 |
| Amphastar Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.23 | 0.0% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $32.56 | 0.0% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $20.71 | 0.0% | 1 | 2025 |
| Rhythm Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.17 | 0.0% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $17.62 | 0.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.31 | 0.0% | 1 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.77 | 0.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.04 | 0.0% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $14.33 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $76,644.44 | 25 |
| Travel and Lodging | $12,266.37 | 21 |
| Food and Beverage | $9,126.42 | 305 |
| Honoraria | $6,490.00 | 3 |
| Education | $149.56 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $39,648.71 | 52 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $30,102.23 | 47 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $29,510.40 | 54 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $1,651.30 | 3 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $413.14 | 28 | 2025 |
Source payment records
|
|||||
| MYALEPT Normalized: myalept |
Drug | Chiesi USA, Inc. | $321.97 | 2 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $310.22 | 12 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $302.57 | 14 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $246.14 | 17 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $239.58 | 15 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $188.31 | 11 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $168.73 | 12 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $167.51 | 11 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $146.10 | 10 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $144.06 | 10 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $116.09 | 6 | 2025 |
Source payment records
|
|||||
| GENOTROPIN Normalized: genotropin |
Drug | PFIZER INC. | $90.39 | 5 | 2025 |
Source payment records
|
|||||
| SOMAVERT Normalized: somavert |
Drug | PFIZER INC. | $90.39 | 5 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $87.57 | 4 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $76.53 | 6 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $64.93 | 4 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $64.93 | 4 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $64.93 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $60.74 | 3 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $49.64 | 3 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $44.28 | 3 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $32.56 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $23.57 | 1 | 2025 |
Source payment records
|
|||||
| MYCAPSSA Normalized: mycapssa |
Drug | Chiesi USA, Inc. | $22.10 | 2 | 2025 |
Source payment records
|
|||||
| JUXTAPID Normalized: juxtapid |
Drug | Chiesi USA, Inc. | $21.97 | 1 | 2025 |
Source payment records
|
|||||
| CRENESSITY Normalized: crenessity |
Drug | Neurocrine BioSciences, Inc. | $20.71 | 1 | 2025 |
Source payment records
|
|||||
| IMCIVREE Normalized: imcivree |
Drug | Rhythm Pharmaceuticals, Inc. | $18.17 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $16.77 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.04 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.04 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $14.33 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $13.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 123 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 78 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 71 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 818 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 109 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 626 | exact normalized | Medicare Part D |
| UNITHROID unithroid |
2025 | Unithroid | 2024 | 62 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
626 | 144 |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | UNITHROID open payments reported associated product |
CMS Open Payments — General Payments 7282 supporting records · 3230 recipient NPIs · example record 1220525525 |
Unithroid · 2024 Exact normalized brand match · 1 Part D row |
62 | 18 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
78 | 22 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
123 | 31 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
71 | 15 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
50 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
818 | 184 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
109 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ozempic | Semaglutide | 818 | 184 |
| Synthroid | Levothyroxine Sodium | 626 | 144 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 504 | 163 |
| Levothyroxine Sodium | Levothyroxine Sodium | 460 | 126 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 408 | 86 |
| Metformin Hcl | Metformin Hcl | 370 | 109 |
| Gabapentin | Gabapentin | 296 | 62 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 295 | 103 |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 260 | 62 |
| Humalog | Insulin Lispro | 242 | 90 |
| Farxiga | Dapagliflozin Propanediol | 241 | 58 |
| Humulin R U-500 | Insulin Regular, Human | 228 | 47 |
| Tresiba Flextouch U-200 | Insulin Degludec | 223 | 62 |
| Cequr Simplicity | Bolus Insulin Pump, 200 Unit | 218 | 83 |
| Atorvastatin Calcium | Atorvastatin Calcium | 202 | 63 |
| Novolog | Insulin Aspart | 201 | 79 |
| Insulin Lispro | Insulin Lispro | 199 | 63 |
| Novolog Flexpen | Insulin Aspart | 198 | 77 |
| Mounjaro | Tirzepatide | 196 | 40 |
| Humalog Kwikpen U-100 | Insulin Lispro | 192 | 77 |
| Tresiba Flextouch U-100 | Insulin Degludec | 181 | 69 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 159 | 68 |
| Vascepa | Icosapent Ethyl | 155 | 31 |
| Losartan Potassium | Losartan Potassium | 141 | 36 |
| Liothyronine Sodium | Liothyronine Sodium | 132 | 35 |
| Testosterone Cypionate | Testosterone Cypionate | 128 | 32 |
| Jardiance | Empagliflozin | 123 | 31 |
| Methimazole | Methimazole | 121 | 27 |
| Trulicity | Dulaglutide | 116 | 27 |
| Rybelsus | Semaglutide | 109 | 24 |
| Amlodipine Besylate | Amlodipine Besylate | 95 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 95 | 25 |
| Hydrocortisone | Hydrocortisone | 94 | 24 |
| Lisinopril | Lisinopril | 79 | 24 |
| Kerendia | Finerenone | 78 | 22 |
| Metformin Hcl Er | Metformin Hcl | 75 | 20 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 74 | 37 |
| Nexletol | Bempedoic Acid | 71 | 15 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 68 | 36 |
| Repatha Sureclick | Evolocumab | 65 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | 15 |
| Insulin Aspart | Insulin Aspart | 62 | 27 |
| Unithroid | Levothyroxine Sodium | 62 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 59 | 25 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 14 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 58 | 15 |
| Trazodone Hcl | Trazodone Hcl | 57 | 14 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 54 | 23 |
| Pregabalin | Pregabalin | 53 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 52 | 16 |
| Glipizide | Glipizide | 52 | 12 |
| Fiasp | Insulin Aspart (Niacinamide) | 50 | 18 |
| Januvia | Sitagliptin Phosphate | 50 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 41 | 16 |
| Ezetimibe | Ezetimibe | 40 | suppressed |
| Testosterone | Testosterone | 40 | 12 |
| Calcitriol | Calcitriol | 39 | suppressed |
| Dexamethasone | Dexamethasone | 39 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 37 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 36 | 13 |
| Insulin Aspart Flexpen | Insulin Aspart | 35 | 20 |
| Omnipod 5 Dexg7g6 Intro(Gen 5) | Insulin Pmp Cart,aut,g6/7,cntr | 35 | 35 |
| Potassium Chloride | Potassium Chloride | 35 | 11 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 34 | 11 |
| Nexlizet | Bempedoic Acid/Ezetimibe | 34 | suppressed |
| V-Go 40 | Sub-Q Insulin Device, 40 Unit | 34 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 32 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 32 | suppressed |
| Cequr Simplicity Inserter | Diabetic Supplies,miscell | 31 | 28 |
| Pen Needle | Pen Needle, Diabetic | 31 | 14 |
| Simvastatin | Simvastatin | 29 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Victoza 3-Pak | Liraglutide | 27 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 26 | 15 |
| Fluconazole | Fluconazole | 26 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 23 | suppressed |
| Prednisone | Prednisone | 23 | suppressed |
| Armour Thyroid | Thyroid,pork | 22 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | suppressed |
| Np Thyroid | Thyroid,pork | 22 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 22 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 21 | suppressed |
| Admelog | Insulin Lispro | 20 | suppressed |
| Omeprazole | Omeprazole | 20 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 19 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 18 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Cabergoline | Cabergoline | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 15 | suppressed |
| Repatha Pushtronex | Evolocumab | 15 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Furosemide | Furosemide | 14 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 14 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Calcium Acetate | Calcium Acetate | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 13 | suppressed |
| Wegovy | Semaglutide | 13 | suppressed |
| Adthyza | Thyroid,pork | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | 12 |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Insulin Degludec Pen (U-100) | Insulin Degludec | 12 | suppressed |
| Tymlos | Abaloparatide | 12 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $104,676.79 · 358 records | Novo Nordisk Inc | AFREZZA, AREXVY, CRENESSITY, CRYSVITA, CeQur Simplicity, Dexcom G6 Transmitter, Flector, GENOTROPIN, GVOKE HYPOPEN, IMCIVREE, ISTURISA, JARDIANCE, JATENZO, JUXTAPID, Kerendia, Korlym, LEQVIO, Licart, MINIMED 780G, MYALEPT, MYCAPSSA, NEXLETOL, Omnipod, Ozempic, RECORLEV, REZDIFFRA, Rybelsus, SHINGRIX, SOMAVERT, STRENSIQ, SYNTHROID, Senza, TEPEZZA, Tirosint, Tlando, UNITHROID, XYOSTED, Yorvipath, t:slim X2 Insulin Pump with Control-IQ | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error